Literature DB >> 25564695

Intriguing model significantly reduces boarding of psychiatric patients, need for inpatient hospitalization.

.   

Abstract

As new approaches to the care of psychiatric emergencies emerge, one solution is gaining particular traction. Under the Alameda model, which has been put into practice in Alameda County, CA, patients who are brought to regional EDs with emergency psychiatric issues are quickly transferred to a designated emergency psychiatric facility as soon as they are medically stabilized. This alleviates boarding problems in area EDs while also quickly connecting patients with specialized care. With data in hand on the model's effectiveness, developers believe the approach could alleviate boarding problems in other communities as well. The model is funded by through a billing code established by California's Medicaid program for crisis stabilization services. Currently, only 22% of the patients brought to the emergency psychiatric facility ultimately need to be hospitalized; the other 78% are able to go home or to an alternative situation. In a 30-day study of the model, involving five community hospitals in Alameda County, CA, researchers found that ED boarding times were as much as 80% lower than comparable ED averages, and that patients were stabilized at least 75% of the time, significantly reducing the need for inpatient hospitalization.

Entities:  

Mesh:

Year:  2015        PMID: 25564695

Source DB:  PubMed          Journal:  ED Manag        ISSN: 1044-9167


  2 in total

1.  Emergency psychiatric assessment, treatment, and healing (EmPATH) unit decreases hospital admission for patients presenting with suicidal ideation in rural America.

Authors:  Allison K Kim; J Priyanka Vakkalanka; Paul Van Heukelom; Jodi Tate; Sangil Lee
Journal:  Acad Emerg Med       Date:  2021-09-07       Impact factor: 3.451

2.  Factors associated with prolonged length of stay in the psychiatric emergency service.

Authors:  Chun-Chi Hsu; Hung-Yu Chan
Journal:  PLoS One       Date:  2018-08-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.